FDA Perspective on JAK Inhibitor Development & Dermatologic Disorders

Time: 2:15 pm
day: Day Two


  • Considering what clinical endpoints the FDA will accept across multiple disciplines within JAK inhibitor drug development to accelerate delivery to market
  • Q&A Time: An extended 15 minute session post presentation to alleviate all JAK inhibitor pipeline queries and save labor downstream